Exicure, Inc. XCUR 深 沪
已收盘 05-15 16:00:00 美东时间
2.84
-0.340
-10.69%
华盛通- 最 高3.02
- 今 开3.00
- 成交量 3.31万股
- 最 低 2.7826
- 昨 收 3.18
- 总市值 1810.19万
- 52周最高 10.80
- 市盈率 静 --
- 换手率 0.52%
- 52周最低 2.7826
- 委 比 0.99%
- 总股本 637.39万
- 历史最高 576.00
- 量 比 3.70
- 振 幅 7.47%
- 历史最低 1.457
- 每 手 1
- 风险率 1.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Galmed Pharmaceuticals (NASDAQ:GLMD) stock increased by 83.2% to $1.14...
04-09 20:05
Exicure Reaches Settlement In Shareholder Derivative Lawsuit, Agrees To Governance Reforms And $675K Legal Fee Payment
Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the following notice:TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF EXICURE, INC.
04-03 04:02
Exicure Q4 EPS $(0.22) Up From $(3.39) YoY.
Exicure (NASDAQ:XCUR) reported quarterly losses of $(0.22) per share. This is a 93.51 percent increase over losses of $(3.39) per share from the same period last year.
03-26 04:35
On Feb 11, The Board Of Directors Of Exicure Appointed Jung Soo Kim As CEO And President; Appointed Gyuyeob Lee As Interim CFO; Andy Yoo Resigns As CEO And President; Seung Ik Baik Resigned As CFO
On February 11, 2026, the board of directors (the "Board") of Exicure, Inc. (the "Company") appointed Jung Soo Kim as the Chief Executive Officer and President of the Company, and also appointed Gyuyeob Lee as the
02-18 06:38
Market-Moving News for December 9th
XCUR: 176% | Exicure shares are trading higher after the company announced results from its completed Phase 2 trial evaluating burixafor combination with propranolol and granulocyte colony-stimulating factor for the
2025-12-09 20:21
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Praxis Precision Medicine (NASDAQ:PRAX) shares moved upwards by 33.6% ...
2025-12-06 01:05
Exicure Says Ongoing Phase 2 Study Of Burixafor In Autologous Stem Cell Transplant For Multiple Myeloma Nears Key Readout
Burixafor Phase 2 Trial in Multiple Myeloma Nears Key Clinical ReadoutExicure's ongoing Phase 2 study (NCT05561751) is a randomized, open-label, multicenter trial evaluating burixafor, a small molecule CXCR4 antagonist,
2025-10-06 19:04
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
Exicure, Inc. announced progress for its lead program, burixafor, with Phase 2 data readout nearing completion for multiple myeloma. interim results show 100% successful stem cell mobilization. The company plans to expand burixafor into sickle cell disease and AML. New leadership appointments, including Josephine Cardarelli, Niña Caculitan, and Devki Sukhtankar, enhance drug development capabilities. Burixafor, a CXCR4 antagonist, aims to improve...
2025-10-06 11:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers IO Biotech (NASDAQ:IOBT) stock rose 52.5% to $2.76 during Monday's pre...
2025-08-11 20:08
Exicure GAAP EPS of -$0.41
Exicure press release (NASDAQ:XCUR): Q2 GAAP EPS of -$0.41. Cash Position: Cash and cash equivalents were $7.9 million as of June 30, 2025, as compared to $12.5 million as of December 31, 2024. More o...
2025-08-11 17:14
